Standardized protocols for photocarcinogenesis safety testing

P. Donald Forbes, Janusz Z. Beer, Homer S. Black, Jean Pierre Cesarini, Curtis A. Cole, Ronald E. Davies, John M. Davitt, Frank DeGruijl, John Epstein, Anny Fourtanier, Adèle Green, Thomas Koval, Ronald D. Ley, Romano Mascotto, Warwick Morison, Robert Osterberg, David Sliney, Frederick Urbach, Jan C. Van Der Leun, Antony R. Young

Research output: Contribution to journalArticle

Abstract

Solar ultraviolet radiation (UVR) is recognized as a major cause of non-melanoma skin cancer in man. Skin cancer occurs most frequently in the most heavily exposed areas and correlates with degree of outdoor exposure. The incidence of skin cancer is also increased by contact with photosensitizing drugs and chemicals such as psoralens, coal tars and petroleum stocks. Other substances which do not act as photosensitizers, such as immunosuppressants taken by organ transplant recipients, also increase the risk of skin cancer. The U.S. Food and Drug Administration requests, on a case-by-case basis, that risk of enhanced photocarcinogenesis is assessed for many classes of drugs. Health Canada's Therapeutic Products Programme has issued a Notice of Intent to regulate pharmaceutical products which may enhance carcinogenicity of the skin induced by ultraviolet radiation. Other national regulatory agencies review such data when they exist, but their own requirements emphasize batteries of short-term in vitro and in vivo tests. While they may support drug development strategies, short-term tests have yet to be validated as predictors of the ability of drugs or chemicals to enhance photocarcinogenesis. Published protocols now describe study designs and procedures capable of determining whether test agents enhance the rate of formation of UVR-induced skin tumors.

Original languageEnglish (US)
JournalFrontiers in bioscience : a journal and virtual library
Volume8
StatePublished - 2003
Externally publishedYes

Fingerprint

Safety testing
Skin Neoplasms
Skin
Safety
Ultraviolet radiation
Pharmaceutical Preparations
Radiation
Coal Tar
Photosensitizing Agents
Petroleum
United States Food and Drug Administration
Immunosuppressive Agents
Transplants
Canada
Solar radiation
Tumors
Health
Incidence
Neoplasms

Keywords

  • Guidelines
  • Laboratory Models
  • Photocarcinogenesis
  • Protocols
  • Review
  • Safety Testing
  • Toxicology
  • Uv Radiation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Forbes, P. D., Beer, J. Z., Black, H. S., Cesarini, J. P., Cole, C. A., Davies, R. E., ... Young, A. R. (2003). Standardized protocols for photocarcinogenesis safety testing. Frontiers in bioscience : a journal and virtual library, 8.

Standardized protocols for photocarcinogenesis safety testing. / Forbes, P. Donald; Beer, Janusz Z.; Black, Homer S.; Cesarini, Jean Pierre; Cole, Curtis A.; Davies, Ronald E.; Davitt, John M.; DeGruijl, Frank; Epstein, John; Fourtanier, Anny; Green, Adèle; Koval, Thomas; Ley, Ronald D.; Mascotto, Romano; Morison, Warwick; Osterberg, Robert; Sliney, David; Urbach, Frederick; Van Der Leun, Jan C.; Young, Antony R.

In: Frontiers in bioscience : a journal and virtual library, Vol. 8, 2003.

Research output: Contribution to journalArticle

Forbes, PD, Beer, JZ, Black, HS, Cesarini, JP, Cole, CA, Davies, RE, Davitt, JM, DeGruijl, F, Epstein, J, Fourtanier, A, Green, A, Koval, T, Ley, RD, Mascotto, R, Morison, W, Osterberg, R, Sliney, D, Urbach, F, Van Der Leun, JC & Young, AR 2003, 'Standardized protocols for photocarcinogenesis safety testing', Frontiers in bioscience : a journal and virtual library, vol. 8.
Forbes PD, Beer JZ, Black HS, Cesarini JP, Cole CA, Davies RE et al. Standardized protocols for photocarcinogenesis safety testing. Frontiers in bioscience : a journal and virtual library. 2003;8.
Forbes, P. Donald ; Beer, Janusz Z. ; Black, Homer S. ; Cesarini, Jean Pierre ; Cole, Curtis A. ; Davies, Ronald E. ; Davitt, John M. ; DeGruijl, Frank ; Epstein, John ; Fourtanier, Anny ; Green, Adèle ; Koval, Thomas ; Ley, Ronald D. ; Mascotto, Romano ; Morison, Warwick ; Osterberg, Robert ; Sliney, David ; Urbach, Frederick ; Van Der Leun, Jan C. ; Young, Antony R. / Standardized protocols for photocarcinogenesis safety testing. In: Frontiers in bioscience : a journal and virtual library. 2003 ; Vol. 8.
@article{7a4225496d4a475c8ac03e252196144e,
title = "Standardized protocols for photocarcinogenesis safety testing",
abstract = "Solar ultraviolet radiation (UVR) is recognized as a major cause of non-melanoma skin cancer in man. Skin cancer occurs most frequently in the most heavily exposed areas and correlates with degree of outdoor exposure. The incidence of skin cancer is also increased by contact with photosensitizing drugs and chemicals such as psoralens, coal tars and petroleum stocks. Other substances which do not act as photosensitizers, such as immunosuppressants taken by organ transplant recipients, also increase the risk of skin cancer. The U.S. Food and Drug Administration requests, on a case-by-case basis, that risk of enhanced photocarcinogenesis is assessed for many classes of drugs. Health Canada's Therapeutic Products Programme has issued a Notice of Intent to regulate pharmaceutical products which may enhance carcinogenicity of the skin induced by ultraviolet radiation. Other national regulatory agencies review such data when they exist, but their own requirements emphasize batteries of short-term in vitro and in vivo tests. While they may support drug development strategies, short-term tests have yet to be validated as predictors of the ability of drugs or chemicals to enhance photocarcinogenesis. Published protocols now describe study designs and procedures capable of determining whether test agents enhance the rate of formation of UVR-induced skin tumors.",
keywords = "Guidelines, Laboratory Models, Photocarcinogenesis, Protocols, Review, Safety Testing, Toxicology, Uv Radiation",
author = "Forbes, {P. Donald} and Beer, {Janusz Z.} and Black, {Homer S.} and Cesarini, {Jean Pierre} and Cole, {Curtis A.} and Davies, {Ronald E.} and Davitt, {John M.} and Frank DeGruijl and John Epstein and Anny Fourtanier and Ad{\`e}le Green and Thomas Koval and Ley, {Ronald D.} and Romano Mascotto and Warwick Morison and Robert Osterberg and David Sliney and Frederick Urbach and {Van Der Leun}, {Jan C.} and Young, {Antony R.}",
year = "2003",
language = "English (US)",
volume = "8",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Standardized protocols for photocarcinogenesis safety testing

AU - Forbes, P. Donald

AU - Beer, Janusz Z.

AU - Black, Homer S.

AU - Cesarini, Jean Pierre

AU - Cole, Curtis A.

AU - Davies, Ronald E.

AU - Davitt, John M.

AU - DeGruijl, Frank

AU - Epstein, John

AU - Fourtanier, Anny

AU - Green, Adèle

AU - Koval, Thomas

AU - Ley, Ronald D.

AU - Mascotto, Romano

AU - Morison, Warwick

AU - Osterberg, Robert

AU - Sliney, David

AU - Urbach, Frederick

AU - Van Der Leun, Jan C.

AU - Young, Antony R.

PY - 2003

Y1 - 2003

N2 - Solar ultraviolet radiation (UVR) is recognized as a major cause of non-melanoma skin cancer in man. Skin cancer occurs most frequently in the most heavily exposed areas and correlates with degree of outdoor exposure. The incidence of skin cancer is also increased by contact with photosensitizing drugs and chemicals such as psoralens, coal tars and petroleum stocks. Other substances which do not act as photosensitizers, such as immunosuppressants taken by organ transplant recipients, also increase the risk of skin cancer. The U.S. Food and Drug Administration requests, on a case-by-case basis, that risk of enhanced photocarcinogenesis is assessed for many classes of drugs. Health Canada's Therapeutic Products Programme has issued a Notice of Intent to regulate pharmaceutical products which may enhance carcinogenicity of the skin induced by ultraviolet radiation. Other national regulatory agencies review such data when they exist, but their own requirements emphasize batteries of short-term in vitro and in vivo tests. While they may support drug development strategies, short-term tests have yet to be validated as predictors of the ability of drugs or chemicals to enhance photocarcinogenesis. Published protocols now describe study designs and procedures capable of determining whether test agents enhance the rate of formation of UVR-induced skin tumors.

AB - Solar ultraviolet radiation (UVR) is recognized as a major cause of non-melanoma skin cancer in man. Skin cancer occurs most frequently in the most heavily exposed areas and correlates with degree of outdoor exposure. The incidence of skin cancer is also increased by contact with photosensitizing drugs and chemicals such as psoralens, coal tars and petroleum stocks. Other substances which do not act as photosensitizers, such as immunosuppressants taken by organ transplant recipients, also increase the risk of skin cancer. The U.S. Food and Drug Administration requests, on a case-by-case basis, that risk of enhanced photocarcinogenesis is assessed for many classes of drugs. Health Canada's Therapeutic Products Programme has issued a Notice of Intent to regulate pharmaceutical products which may enhance carcinogenicity of the skin induced by ultraviolet radiation. Other national regulatory agencies review such data when they exist, but their own requirements emphasize batteries of short-term in vitro and in vivo tests. While they may support drug development strategies, short-term tests have yet to be validated as predictors of the ability of drugs or chemicals to enhance photocarcinogenesis. Published protocols now describe study designs and procedures capable of determining whether test agents enhance the rate of formation of UVR-induced skin tumors.

KW - Guidelines

KW - Laboratory Models

KW - Photocarcinogenesis

KW - Protocols

KW - Review

KW - Safety Testing

KW - Toxicology

KW - Uv Radiation

UR - http://www.scopus.com/inward/record.url?scp=17044441301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044441301&partnerID=8YFLogxK

M3 - Article

VL - 8

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -